Annual CFF:
$72.40M+$65.50M(+949.41%)Summary
- As of today, SPRY annual cash from financing is $72.40 million, with the most recent change of +$65.50 million (+949.41%) on December 31, 2024.
- During the last 3 years, SPRY annual cash from financing has risen by +$19.24 million (+36.20%).
- SPRY annual cash from financing is now -82.28% below its all-time high of $408.51 million, reached on December 1, 2020.
Performance
SPRY Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly CFF:
$100.05M+$97.35M(+3609.49%)Summary
- As of today, SPRY quarterly cash from financing is $100.05 million, with the most recent change of +$97.35 million (+3609.49%) on September 30, 2025.
- Over the past year, SPRY quarterly cash from financing has increased by +$99.36 million (+14612.50%).
- SPRY quarterly cash from financing is now at all-time high.
Performance
SPRY Quarterly Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$174.38M+$99.36M(+132.45%)Summary
- As of today, SPRY TTM cash from financing is $174.38 million, with the most recent change of +$99.36 million (+132.45%) on September 30, 2025.
- Over the past year, SPRY TTM cash from financing has increased by +$171.09 million (+5203.62%).
- SPRY TTM cash from financing is now at all-time high.
Performance
SPRY TTM Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
SPRY Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +949.4% | +10000.0% | +5203.6% |
| 3Y3 Years | +36.2% | +6529.6% | +6301.4% |
| 5Y5 Years | +740.9% | - | - |
SPRY Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -62.0% | +949.4% | at high | +6529.6% | at high | +6301.4% |
| 5Y | 5-Year | -82.3% | +949.4% | at high | +6529.6% | at high | +6301.4% |
| All-Time | All-Time | -82.3% | +949.4% | at high | +6529.6% | at high | +6301.4% |
SPRY Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | $100.05M(+3609.5%) | $174.38M(+132.5%) |
| Jun 2025 | - | $2.70M(+272.0%) | $75.02M(+3.0%) |
| Mar 2025 | - | $725.00K(-99.0%) | $72.87M(+0.6%) |
| Dec 2024 | $72.40M(+949.4%) | $70.92M(>+9900.0%) | $72.40M(+2101.9%) |
| Sep 2024 | - | $680.00K(+24.8%) | $3.29M(-6.8%) |
| Jun 2024 | - | $545.00K(+111.2%) | $3.53M(-39.6%) |
| Mar 2024 | - | $258.00K(-85.7%) | $5.84M(-15.4%) |
| Dec 2023 | $6.90M(-96.4%) | $1.80M(+96.0%) | $6.90M(+35.4%) |
| Sep 2023 | - | $921.00K(-67.7%) | $5.09M(+94.7%) |
| Jun 2023 | - | $2.85M(+116.4%) | $2.62M(+404.3%) |
| Mar 2023 | - | $1.32M(+184.8%) | -$860.00K(+69.4%) |
| Dec 2022 | $190.73M | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | -$1.56M(-149.8%) | -$2.81M(-153.8%) |
| Jun 2022 | - | -$623.00K(+31.4%) | -$1.11M(-567.5%) |
| Mar 2022 | - | -$908.00K(-430.2%) | -$166.00K(-127.0%) |
| Dec 2021 | $53.16M(-87.0%) | - | - |
| Dec 2021 | - | $275.00K(+85.8%) | $614.00K(+81.1%) |
| Sep 2021 | - | $148.00K(-53.6%) | $339.00K(+77.5%) |
| Jun 2021 | - | $319.00K(+349.2%) | $191.00K(-98.4%) |
| Mar 2021 | - | -$128.00K(-101.1%) | $11.80M(-64.5%) |
| Dec 2020 | $408.51M(+4644.6%) | - | - |
| Jun 2020 | - | $11.93M(-44.0%) | $33.25M(+56.0%) |
| Mar 2020 | - | $21.32M | $21.32M |
| Dec 2019 | $8.61M(-55.6%) | - | - |
| Dec 2018 | $19.40M | - | - |
FAQ
- What is ARS Pharmaceuticals, Inc. annual cash from financing?
- What is the all-time high annual cash from financing for ARS Pharmaceuticals, Inc.?
- What is ARS Pharmaceuticals, Inc. annual cash from financing year-on-year change?
- What is ARS Pharmaceuticals, Inc. quarterly cash from financing?
- What is the all-time high quarterly cash from financing for ARS Pharmaceuticals, Inc.?
- What is ARS Pharmaceuticals, Inc. quarterly cash from financing year-on-year change?
- What is ARS Pharmaceuticals, Inc. TTM cash from financing?
- What is the all-time high TTM cash from financing for ARS Pharmaceuticals, Inc.?
- What is ARS Pharmaceuticals, Inc. TTM cash from financing year-on-year change?
What is ARS Pharmaceuticals, Inc. annual cash from financing?
The current annual cash from financing of SPRY is $72.40M
What is the all-time high annual cash from financing for ARS Pharmaceuticals, Inc.?
ARS Pharmaceuticals, Inc. all-time high annual cash from financing is $408.51M
What is ARS Pharmaceuticals, Inc. annual cash from financing year-on-year change?
Over the past year, SPRY annual cash from financing has changed by +$65.50M (+949.41%)
What is ARS Pharmaceuticals, Inc. quarterly cash from financing?
The current quarterly cash from financing of SPRY is $100.05M
What is the all-time high quarterly cash from financing for ARS Pharmaceuticals, Inc.?
ARS Pharmaceuticals, Inc. all-time high quarterly cash from financing is $100.05M
What is ARS Pharmaceuticals, Inc. quarterly cash from financing year-on-year change?
Over the past year, SPRY quarterly cash from financing has changed by +$99.36M (+14612.50%)
What is ARS Pharmaceuticals, Inc. TTM cash from financing?
The current TTM cash from financing of SPRY is $174.38M
What is the all-time high TTM cash from financing for ARS Pharmaceuticals, Inc.?
ARS Pharmaceuticals, Inc. all-time high TTM cash from financing is $174.38M
What is ARS Pharmaceuticals, Inc. TTM cash from financing year-on-year change?
Over the past year, SPRY TTM cash from financing has changed by +$171.09M (+5203.62%)